Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who cares about any fundamental moves or bids on the table until the company gets delisted w the takeover, until then MM tricks and nonsense moves carry the stock price. No real valuation, no real investment approach, pink sheets=corrupt sheets full of illetarate gamblers. No need to discuss anymore here. It is here for the ones who can see. Good luck.
Actually, it is highly relevant for a company which is on the verge of closing the J&J bs for good and executing on its business plan. Working capital is a fundamental part of the story and kudos to gem for keeping this in for full transparency.
It is totally the opposite. Anyone who made a business plan and who had to put that on the shelf would know about this. Good luck!
It is very clearly the opposite here. It is called consistency, sticking with the business plan. They were planning to make a huge jump in sales if it were not the unfair tactics of J&J. For the last how many years, they could not push the button in that plan and that plan required significant working capital given the ramp up in sales. Seeing the same working capital figure when the company's have been stagnant for years due to outsiders' dirty tactics is actually a big positive and gives me comfort on their trust to get business plan. Thanks for checking those and giving me more comfort which I did not need more of to be honest.
What 56mn? The one that was discussed several times here? It means absolute nothing without the sales info. They will make revenues multiple of that figure if they get up to 56mn wc levels.
Also, charts mean absolute nothing when there is an outright bidding war.
Lol:) This is the reason why most will miss this run up. Watch and learn.
Lol:) there have been several updates on this and also on top of these. Just take a look and digest the last few PRs.
Shorts are done. They don't know it yet but heat is going up.
Let's pls look at some of the methodologies commonly used in "how to value companies"? Do you think Amazon is trading at these levels due to their existing profitability or margins? Projections and prospects are some clues. Obviously, they have very clear financials that the suitors are chasing them. Good luck!
Really? How do you know that it will wipe out shareholder value? How do you know at what price will this be issued? How many years of lock up will this have? What will be the use of this $5mn? The current Macao of the company is less than 8mn, despite all these catalysts and offer(s) on the table, it is crazy cheap. You were waiting for 5 cents but be ready for double digits very very soon.
When was the Supreme Court decision taken? How much money was left in this little company after several years of dragging to launch an aggressive campaign? Why is Genprecis being regarded as the new generation? How different it is from others? When is the settlement w J&J? 17mn order is approved by governments in SA and being delivered now? Why is there an order on the table at a substantial premium?
When are we going to be in 2017? We are almost done 2/3rds of 2017?
It is like a circular in excel here...Why didn't it translate into sales so far? There is a very clear reason starting with J&J...As a shareholder one must be very excited what that working capital will translate into. We will talk again when this doubles from here soon. Good luck!
Again, I would highly recommend you look at how working capital is accounted, how it is calculated, why is t used, etc. What's the company saying? For sales growth. Everything is so straightforward and obvious but as w many things, it is being taken out of context and trying to be used for other purposes. A shareholder should be very excited if this company has 56mn working capital needs as the sales would be substantially above that under that case. Good luck this week and following weeks.
Avalanche is coming and shorts are still in ignorance in my view. They will learn a very expensive lesson. 5 to 9 and then 15 and then...assuming that things are the same when the lawsuits are almost over, offers are on the table, genprecis on its way is foolish at best.
56mn comes from the projections of the company on future sales, it is as straight as it gets.
Where is your proof? If you are sure, why don't you take the litigation path? Since you are a friend of him, you should have a good handle on that.
This is absolute nonsense. 20mn in sales and 20mn in working capital?
Working capital does not work that way. Pls google and see how companies finance their growth and sales increases, timing of working capital needs etc. I would more focus on what $56 mn would bring in sales rather than he WC amount. This should help your analysis. Good luck.
Shorts are done but they do not realise it yet. The anxiety increase when this blows through double digits comfortably. Watch and learn. Complacency is a dangerous habit in stock markets.
If you read the paragraph that was quoted in, you will see that it is management's projection for the new products and pipeline. You will get the details of what it means as the plans crystallise on launch and sales of Genprecise. It is that simple and very prudent of management to show this figure ahead of everything go real investors.
Lol:) nothing happened such as an industry giant unfairly pushed them off the market w several dirty tactics. From here to February, watch for the final settlement. Punch your tickets for the show or just watch it. The show just started.
This is not relevant and does nothing to do w the current situation of the company. When are we going to be in 2017 in your posts?
That neck is going to be in trouble more:) it does not look like it is carrying much on top in any case!
Shorts are done but they don't realise it yet...
Yes, real massive and substantial. Hold on the offer at hand is substantially November the current SP as well. Shorting seems better though. You are right.
Yes likely. Shorting is a wise decision.
Trade debt means working capital. Hope this helps.
You make some sales projections and then you come up with an estimate of working capital to achieve those sales figures, Hope this helps.
Fully agree, shorting could be wise at this point.
Lol:) they are really BS. Good luck.
lol:) this is a good one Nons...Everyday is a new day and everyday is another potential suitor day. "At play" for now. The offer was in an email, nope; where is the valuation expert, here they are; no other bidder, another one any day now....
The offer at hand is "substantially above" the current price, another one on the way and many other significant catalysts. This should be well into midteeens now in my view. A lot of buying going on if you look at Level 2.
The company is going into an auction process in front of your eyes. Watch and learn.
It is just getting started. Watch out.
If you google working capital, you will find the right answer. Then, pay attention to what genprecise is.
Do you know how much sales and profit that 56mn will bring? This is actually great news if they can get there. Do you realise that? It actually provides my point. Train is leaving, wake up time in my view.
Yesterday's very important announcement. Investors should pay attention, train will leave the station in my view very soon.
Company Begins Soliciting Offers from Valuation Experts to Better Value DECN and Its Properties and to Value Settlement Options in Patent Infringement Suit vs. J&J
LOS ANGELES, CA / ACCESSWIRE / August 2, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN), a manufacturer, quality plan administrator, and exclusive worldwide sales, service, and regulatory process agent for GenUltimate!™ glucose test strips, the pre-market ready GenSure!™ and GenChoice!™ test strips, and the revolutionary meter and test strip system GenPrecis! GenUltimate!™ glucose test strips work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters. The company today addresses shareholders, investors and interested parties regarding a previously unsolicited M&A offer.
The Board of Directors of Decision Diagnostics Corp. reviewed the formal written offer received, and Mr. Berman took the opportunity to question the proposed M&A partner. Ultimately, the Board determined that while the offer is substantially above the current stock selling price, the offer is currently deficient in several respects.
Keith Berman, CEO of DECN, stated, "We have made it clear to our proposed partner that their well-thought offer does not take into account several factors which would lead to a much higher valuation. First, the company is in the process of concluding a raise of strategic capital and has received a subscription for $3.25 million which the company desires to close prior to its filing on August 14, 2017 of its 2Q 2017 Quarterly Report; and a second subscription for more than $2.5 million under the same terms."
Additionally, the Board also determined that it will not counter offer the proposed M&A partner until they receive a prepared valuation, which they will commission soon, or a revised offer. To that end, the company has already received a proposal for this valuation from a large accounting firm. The company has been informed that another offer may be made in the coming days by another type of M&A partner.
Mr. Berman concluded, "The offer received does not take into account any settlement expected from our litigation with the Lifescan division of Johnson + Johnson. Thus, we have communicated to the proposed M&A partner that the Board is neither accepting nor rejecting their current offer. While we intend to stay in regular contact with our proposed partner, the Board believes that prior to the conclusion of our valuation exercise, we anticipate receiving a revised offer."
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of July 31, 2017, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
Yeah sure...
Lol, it is quiet for a reason...the news will spread more tomorrow, more the day after and perhaps on Monday, people will find a new offer together w a revised offer from the existing party...who else can come in to this war? Let's guess...good luck.
Company Begins Soliciting Offers from Valuation Experts to Better Value DECN and Its Properties and to Value Settlement Options in Patent Infringement Suit vs. J&J
LOS ANGELES, CA / ACCESSWIRE / August 2, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN), a manufacturer, quality plan administrator, and exclusive worldwide sales, service, and regulatory process agent for GenUltimate!™ glucose test strips, the pre-market ready GenSure!™ and GenChoice!™ test strips, and the revolutionary meter and test strip system GenPrecis! GenUltimate!™ glucose test strips work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters. The company today addresses shareholders, investors and interested parties regarding a previously unsolicited M&A offer.
The Board of Directors of Decision Diagnostics Corp. reviewed the formal written offer received, and Mr. Berman took the opportunity to question the proposed M&A partner. Ultimately, the Board determined that while the offer is substantially above the current stock selling price, the offer is currently deficient in several respects.
Keith Berman, CEO of DECN, stated, "We have made it clear to our proposed partner that their well-thought offer does not take into account several factors which would lead to a much higher valuation. First, the company is in the process of concluding a raise of strategic capital and has received a subscription for $3.25 million which the company desires to close prior to its filing on August 14, 2017 of its 2Q 2017 Quarterly Report; and a second subscription for more than $2.5 million under the same terms."
Additionally, the Board also determined that it will not counter offer the proposed M&A partner until they receive a prepared valuation, which they will commission soon, or a revised offer. To that end, the company has already received a proposal for this valuation from a large accounting firm. The company has been informed that another offer may be made in the coming days by another type of M&A partner.
Mr. Berman concluded, "The offer received does not take into account any settlement expected from our litigation with the Lifescan division of Johnson + Johnson. Thus, we have communicated to the proposed M&A partner that the Board is neither accepting nor rejecting their current offer. While we intend to stay in regular contact with our proposed partner, the Board believes that prior to the conclusion of our valuation exercise, we anticipate receiving a revised offer."
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of July 31, 2017, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.